The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 678 participants.
Also called NCT01081834
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 678 participants
- Registry
-
NCT01081834
-
- Other papers using this trial's data
- Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Colombia, Estonia, Guatemala, Iceland, India, Lithuania, Malaysia, Mexico, Philippines, Poland, Puerto Rico, Romania, South Africa, South Korea, Spain, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT01081834. Randomized; triple masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2011-08 (actual). Results posted on 2013-06-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Sitagliptin
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01081834- Content hash
23c5a83a07b53202cec13f69c78e4e7407877839aef61196c302c4f2bd8f138c